表紙
市場調查報告書

焦點市場分析:亨丁頓舞蹈症

Market Spotlight: Huntington's Disease

出版商 Datamonitor Healthcare 商品編碼 573554
出版日期 內容資訊 英文 29 Pages
商品交期: 最快1-2個工作天內
價格
焦點市場分析:亨丁頓舞蹈症 Market Spotlight: Huntington's Disease
出版日期: 2020年08月14日內容資訊: 英文 29 Pages
簡介

據估計,2017年全球30歲以上人口中患有亨廷頓舞蹈病的人數為159,410,預計到2026年將增加到184,950。就各地區別來看,北美患病人數最多,而亞洲患病人數最少。臨床開發中的大多數藥物都處於II期,其中兩種藥物處於III期。目標包括亨廷頓蛋白,囊泡單胺轉運蛋白,p38 MAP激酶,SIRT1,血管加壓素受體,semaphorin 4D / CD100,芳基烴受體,NMDA谷氨酸受體,PPARδ,PPARγ等。大多數線藥物是口服的,其他包括鞘內,靜脈內,腦室內和腦室內產品。美國是區域臨床試驗的世界領導者,英國位居歐盟之首。

本報告提供全球亨丁頓舞蹈症治療藥的市場調查,彙整疾病的背景·概要,患病人數的10年預測,開發平台藥物及已上市藥概要,臨床試驗狀況,授權·資產收購等的主要交易趨勢,專利資訊,主要藥物的收益預測等資料。

概要

要點

疾病的背景

治療

  • 霍亂治療
  • 帕金森病治療
  • 行動功能·精神功能障礙

流行病學

已上市藥物

開發平台藥物

近幾年的發展·分析師的見解

  • Nerventra

今後的發展

法律規章上的發展

  • 罕見疾病用醫藥品認證

授權·資產取得契約

  • Alkermes:新的CNS標的的投資·Rodin的收購
  • ■成功概率

本源專利

商機

臨床試驗環境

  • 贊助商:各狀態
  • 贊助商:不同階段

文獻

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DMKC0178508

Huntington's disease (HD) is a rare disorder of the central nervous system (CNS) which causes the degeneration of nerve cells. It is an autosomal dominant disease characterized by involuntary choreatic movements, psychiatric and behavioral disturbances, and dementia. The mean age of symptom onset is 30-50 years. HD is caused by the presence of >40 cytosine-adenine-guanine (CAG) repeats within the Huntingtin gene. The length of the CAG repeats is inversely associated with the age of disease onset - the longer the repeat, the earlier the onset. In the case of juvenile HD (JHD), the length of the repeat is >55 and the disease's symptoms are seen in patients aged <20 years. Learning disabilities and behavioral disturbances are the first symptoms in patients with JHD.

Key Takeaways

Datamonitor Healthcare estimates that in 2019, there were 77,200 prevalent cases of Huntington's disease (HD) in adults aged 30 years and older worldwide, and forecasts that number to increase to 87,700 prevalent cases by 2028.

Northern America is estimated to have the highest disease prevalence (0.0073%), while Asia has the lowest prevalence (0.0004%).

Teva's Austedo and Bausch Health's Xenazine, which target vesicular monamine transporters, are the only marketed drugs for HD. These drugs are administered via the oral route.

The majority of industry-sponsored drugs in active clinical development for HD are in Phase II, with two drugs in Phase III. Therapies in active clinical development for HD focus on targets such as huntingtin, vesicular monamine transporters, p38 MAP kinase, SIRT1, vasopressin receptors, semaphorin 4D/CD100, NMDA glutamate receptor, PPAR delta, and PPAR gamma. The majority of the pipeline drugs are administered via the oral route, with the remainder being intrathecal, intravenous, and intracerebral/cerebroventricular formulations.

High-impact upcoming events for drugs in the HD space comprise topline Phase Ib/IIa trial results for WVE-120101, topline Phase I/II trial results for AMT-130, topline Phase IIa trial results for ANX-005, and topline Phase III trial results for Ingrezza and tominersen.

The overall likelihood of approval of a Phase I neurodegenerative asset is 7.9%, and the average probability a drug advances from Phase III is 49.5%. Drugs, on average, take 10.9 years from Phase I to approval, compared to 9.8 years in the overall neurology space.

The distribution of clinical trials across Phase I-IV indicates that the majority of trials for HD have been in the early and midphases of development, with 77% of trials in Phase I-II, and only 23% in Phase III-IV.

The US has a substantial lead in the number of HD clinical trials globally, while the UK leads the major European markets. Clinical trial activity in the HD space is dominated by completed trials. Pfizer and Teva have the highest number of completed clinical trials for HD, with 14 trials each.

Pfizer and Teva lead industry sponsors with the highest overall number of clinical trials for HD.

TABLE OF CONTENTS

CONTENTS

OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND

  • Subtypes

TREATMENT

  • Treatment of chorea
  • Treatment of parkinsonism
  • Treatment of behavioral and psychiatric dysfunction

EPIDEMIOLOGY

MARKETED DRUGS

PIPELINE DRUGS

KEY UPCOMING EVENTS

PROBABILITY OF SUCCESS

LICENSING AND ASSET ACQUISITION DEALS

  • Alkermes Invests In Novel CNS Targets With Rodin Acquisition

REVENUE OPPORTUNITY

CLINICAL TRIAL LANDSCAPE

  • Sponsors by status
  • Sponsors by phase

BIBLIOGRAPHY

  • Prescription information

APPENDIX

LIST OF FIGURES

  • Figure 1: Trends in prevalent cases of HD, 2019-28
  • Figure 2: Overview of pipeline drugs for HD in the US
  • Figure 3: Pipeline drugs for HD, by company
  • Figure 4: Pipeline drugs for HD, by drug type
  • Figure 5: Pipeline drugs for HD, by classification
  • Figure 6: Key upcoming events in HD
  • Figure 7: Probability of success in the HD pipeline
  • Figure 8: Clinical trials in HD
  • Figure 9: Top 10 drugs for clinical trials in HD
  • Figure 10: Top 10 companies for clinical trials in HD
  • Figure 11: Trial locations in HD
  • Figure 12: HD trials status
  • Figure 13: HD trials sponsors, by phase

LIST OF TABLES

  • Table 1: Prevalent cases of HD, 2019-28
  • Table 2: Prevalence proportions of HD, 2019-28
  • Table 3: Marketed drugs for HD
  • Table 4: Pipeline drugs for HD in the US
  • Table 5: Historical global sales, by drug ($m), 2015-19
  • Table 6: Forecasted global sales, by drug ($m), 2020-24